ARTICLE | Product Development
In BioCentury’s latest clinical report, Merck-Daiichi product scores on PFS after setback at FDA, plus updates from Ascendis, Boehringer, Atea and more
By Lauren Martz, Executive Director of Biopharma Intelligence, and Paul Bonanos, Director of Biopharma Intelligence
September 18, 2024 1:26 AM UTC
New progression-free survival results from the Phase III HERTHENA-Lung02 study add to the body of evidence that could support the first approval of patritumab deruxtecan (HER3-DXd).
The antibody-drug conjugate from Merck & Co. Inc. (NYSE:MRK) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) led to a significant improvement in progression-free survival (PFS) compared with chemotherapy, meeting the trial’s primary endpoint, among patients with EGFR-mutant non-small cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitor treatment…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653576/data-from-merck-daiichi-could-support-first-approval-for-her3-adc